Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open in green
Tue, 8 Nov 09:30 am

Most Asian stock markets have opened the day on a firm note with stock markets in Hong Kong (up 0.7%), Indonesia (up 0.6%) and Malaysia (up 0.6%) leading the gains. However, markets in Japan (down 0.1%) are marginally down. The Indian stock market have also opened the day on a firm note. Stocks in the FMCG and oil and gas space are leading the gains. However, technology stocks are trading weak.

The BSE-Sensex is trading higher by 59 points (0.3%), while the NSE-Nifty is up by around 16 points (0.3%). Mid and small cap stocks are also trading in the green, with the BSE Mid Cap and BSE Small Cap indices up by 0.5% each. The rupee is trading at 49.23 to the US dollar.

Cement stocks have opened the day on a mixed note with Madras Cements, UltraTech Cement and Birla Corporation leading the gains. However, Mangalam Cement and Shree Cement are trading in the red. Madras Cements has declared its results for the second quarter of financial year 2011-12 (2QFY12). The south-based cement company has reported sales revenues of Rs 8.2 bn for the quarter ended September 2011, a 28% YoY growth from the corresponding quarter of the preceding financial year. The strong growth was on the back of a whopping 49% year-on-year (YoY) rise in cement realisations, despite a 9% YoY decline in sales volume. Operating margins almost doubled during the quarter from 16.7% in 2QFY11 to 32.6% in 2QFY12, boosting operating profit by almost 150% YoY to Rs 2.7 bn. At the bottomline, net profits surged by 256% YoY. Net margins rose from 4.8% in 2QFY11 to 13.5% in 2QFY12. During the first half of FY12, sales and net profits increased by 18% YoY and 102% YoY respectively.

Pharma stocks have opened the day on a mixed note with Orchid Chemicals and Aurobindo Pharma trading in the red, while Cadila Healthcare and Piramal Healthcare are trading firm. Piramal Healthcare has announced the second quarter results of the financial year 2011-2012 (2QFY12). The company reported a decline of 35.6% YoY in sales due to the sale of healthcare business in September 2010 and subsequent sale of the diagnostic business. However, comparing the remaining business, the sales grew by 32.1% YoY. This growth was led by over-the-counter (OTC) and critical care business. The overall operating loss stood at Rs 233 m against a loss of Rs 127 m in 2QFY11. The net profits fell to Rs 524 m in 2QFY12 against Rs 124.9 bn in the comparable quarter last year as the latter includes exceptional profits from the sale of the domestic formulation business.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.